| Code | CSB-RA023981MB15HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to tavolimab, targeting TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is an inducible costimulatory receptor expressed primarily on activated T cells that plays a critical role in T cell expansion, survival, and effector function. Upon binding to its ligand OX40L, this receptor enhances T cell-mediated immune responses and promotes the differentiation of memory T cells. TNFRSF4 signaling is particularly relevant in cancer immunology, as its activation can enhance anti-tumor immunity by amplifying T cell responses against malignant cells.
Tavolimab is an investigational agonistic antibody designed to stimulate TNFRSF4 signaling, thereby potentiating T cell activation and proliferation in the tumor microenvironment. This biosimilar provides researchers with a valuable tool for investigating OX40-mediated immunomodulation, exploring combination immunotherapy strategies, and studying T cell biology in oncology and autoimmune disease contexts. The antibody supports studies examining immune checkpoint modulation and tumor immunology mechanisms.
There are currently no reviews for this product.